Robin Jacob, MD
Hematology & Oncology · Cookeville, TNNPI 1962652487
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $21,118 of the $34,021 with a category attached, or 62.1%. 34 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 25.9% of the total. Reporting peaked in 2019 at $8,370 and has fallen 91.6% since, to $700 in 2025.
Across 114 payments — averaging $298.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$9K
- Incyte Corporation$9K
- Amgen$5K
- AstraZeneca$3K
- Exelixis Inc.$2K
- Bayer$2K
- plus $5K from 28 others
Across 3 payments — averaging $42,429 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$127K
What the payments were for
- Consulting fees$21,11862%
- Speaking & faculty fees$7,02021%
- Travel & lodging$3,0059%
- Food & beverage$2,7468%
- Education$1330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 8 | $8,817 |
| Incyte Corporation | 14 | $8,727 |
| Amgen | 7 | $4,544 |
| AstraZeneca | 10 | $3,051 |
| Exelixis Inc. | 6 | $2,051 |
| Bayer | 4 | $1,726 |
| Beigene USA, Inc. | 2 | $1,667 |
| Abbott | 13 | $551 |
| Beigene, Ltd. | 1 | $525 |
| EMD Serono, Inc. | 1 | $500 |
| Astellas Pharma US Inc | 1 | $500 |
| Acist Medical Systems, Inc. | 6 | $346 |
| GSK | 1 | $125 |
| Johnson & Johnson | 3 | $92 |
| Tempus AI, Inc | 3 | $77 |
| Gilead(2 entities) | 4 | $76 |
| E.r. Squibb & Sons, L.L.C. | 4 | $70 |
| Merck | 3 | $66 |
| Novartis | 3 | $60 |
| AVEO Pharmaceuticals, Inc. | 2 | $60 |
| Daiichi Sankyo Inc. | 2 | $51 |
| Bristol Myers Squibb | 2 | $50 |
| Mirati Therapeutics, Inc. | 2 | $42 |
| Pfizer | 2 | $38 |
| Array Biopharma Inc | 1 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $27 |
| Blue Earth Diagnostics | 1 | $25 |
| Taiho Oncology, Inc. | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Biocompatibles, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $18 |
| UCB, Inc. | 1 | $18 |
| CTI Biopharma Corp. | 1 | $14 |
| Genentech USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$34,021 in reported general payments places this provider in the 75th percentile of 251 hematology & oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 18 | $273,825 |
| Imatinib Mesylate | 12 | $3,249 |
| Exemestane | 27 | $3,205 |
| Oxycodone Hcl | 53 | $2,028 |
| Anastrozole | 86 | $1,687 |
| Morphine Sulfate ErMorphine Sulfate | 19 | $1,489 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 38 | $1,154 |
| Letrozole | 46 | $934 |
| Hydroxyurea | 40 | $822 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 14 | $590 |
| Ondansetron OdtOndansetron | 25 | $466 |
| Prochlorperazine Maleate | 39 | $445 |
| Gabapentin | 26 | $346 |
| Ondansetron Hcl | 11 | $240 |
| Dexamethasone | 20 | $185 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $3,051 | $273,82518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 251 hematology & oncology providers in Tennessee.
Other hematology & oncology in Cookeville
- Jonathan AbbasNashville$1.3M
- Alan TanNashville$1.1M
- Kent ShihNashville$900K
- Jason PorterGermantown$756K
- Brian RiniNashville$601K
- Wade IamsNashville$601K
- Krish PatelNashville$531K
- Sandeep RajanNashville$465K
- Todd BauerNashville$357K
- Muhamed BaljevicNashville$313K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.